Opendata, web and dolomites

SEPCELL SIGNED

Title of Proposal: Restoring the immune system homeostasis and organ function in severe community acquired pneumonia- induced sepsis through adipose derived allogeneic stem cells (SEPCELL Proje

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SEPCELL project word cloud

Explore the words cloud of the SEPCELL project. It provides you a very rough idea of what is the project "SEPCELL" about.

patient    stem    possibility    functional    immunomodulatory    models    medical    sepsis    vivo    mortality    patients    mechanism    organ    trial    exaggerated    inflammatory    possess    opportunistic    severe    broad    capacities    reducing    reported    thrombosis    mscs    phagocytosis    cells    standard    acquire    exacerbated    clinical    allogeneic    burden    treatment    complicated    experimental    cap    therapeutic    host    benefit    peptides    normal    immune    rates    bactericidal    initial    anti    modulate    subsequent    occurrence    mediators    leads    huge    infection    vascular    dysregulation    social    dysfunction    ia    levels    ascs    28    sepcell    iib    mesenchymal    lung    injury    cell    50    hyperactivation    micro    extensively    secondary    pro    immunoparalysis    homeostasis    multiple    releasing    infections    unmet    believes    adipose    removal    care    acute    antimicrobial    life    performed    msc    vasodilatation    innovative    immunoactivation    threatening    re    pathophysiologic    restoring    mediated    activation    community    systemic    ss    complete    pneumonia    therapy    immunosuppression    treatments   

Project "SEPCELL" data sheet

The following table provides information about the project.

Coordinator
TIGENIX SA 

Organization address
address: CALLE MARCONI 1
city: TRES CANTONS
postcode: 28760
website: http://www.cellerix.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.sepcell.eu/
 Total cost 12˙000˙695 €
 EC max contribution 5˙369˙886 € (45%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-single-stage_RTD
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TIGENIX SA ES (TRES CANTONS) coordinator 995˙245.00
2    Centre hospitalier universitaire de Limoges FR (Limoges) participant 2˙179˙500.00
3    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 1˙071˙790.00
4    CLINIQUES UNIVERSITAIRES SAINT-LUC BE (BRUXELLES) participant 534˙375.00
5    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 297˙678.00
6    TiGENIX NV BE (LEUVEN) participant 291˙297.00

Map

 Project objective

Sepsis is defined as a systemic inflammatory response to infection, while severe sepsis (SS) is a sepsis complicated by acute organ dysfunction. Lung infections, in particular community-acquire pneumonia (CAP), are the leading cause of SS. The pathophysiologic mechanism of CAP-mediated SS is the complete dysregulation of the patient´s immune system. In an initial phase, the systemic hyperactivation of the host immune response against infection leads to high levels of inflammatory mediators, systemic vasodilatation, micro-vascular thrombosis and organ failure. In a second phase, the exaggerated activation of the immune response leads to a state of ‘immunoparalysis’, which is characterized by the occurrence of secondary, opportunistic infections. This makes CAP-mediated SS a life-threatening condition with mortality rates as high as 28-50%. The current standard of care (infection removal and control, functional support) does not improve the high mortality and, thus, CAP-mediated SS represents a major unmet medical need with a huge social burden. Therefore, treatments with the potential to modulate both the initial exacerbated immunoactivation and the subsequent immunosuppression are needed. Mesenchymal stem cells (MSCs), including adipose mesenchymal stem cells (ASCs), are known for their broad range of immunomodulatory properties, targeting multiple pro- and anti-inflammatory pathways, and possess antimicrobial capacities (releasing bactericidal peptides and promoting the phagocytosis by immune cells). Indeed, therapeutic benefit of MSC treatment in in vivo experimental models of sepsis has been extensively reported. The SEPCELL consortium believes that cell therapy with allogeneic ASCs may be an innovative therapeutic approach in order to re-establish the normal immune homeostasis of CAP-mediated SS patients, reducing organ injury and restoring organ functionality. A phase Ia/IIb clinical trial will be performed to test this possibility.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEPCELL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SEPCELL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More